Glial cell function is impaired in the juvenile form of Batten disease, leading to nerve cell loss, a mouse study has found. The study, “Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neurons,” was appeared in the journal Acta Neuropathologica Communications. Glial cells,…
News
More therapies are now available for the 30 million or so people with rare diseases in the U.S. than ever before, and millions of dollars are being invested in clinical studies that will test new ways of evaluating — and advancing — potential treatments, including the use of natural history…
Brineura (cerliponase alfa), the first therapy approved to treat children with Batten disease, received the 2017 “Best of What’s New” award in the health category by Popular Science, a science and technology magazine. Brineura is BioMarin’s therapeutic product developed to treat the underlying cause of tripeptidyl…
News
#NORDsummit – Despite Criticism, Orphan Drug Act Is Working to Advance Needed Treatments, FDA Says
As Congress begins debate this week to overhaul the U.S. tax code, lawmakers should leave the Orphan Drug Act (ODA) — and the tax incentives it offers pharmaceutical companies to develop therapies for rare diseases — off the table. That’s the message being pushed by the National Organization for…
Gene therapy is able to reduce toxic protein aggregates in a zebrafish model of one form of adult-onset Batten disease, a new study from China shows. The study, “Gene Therapy of Adult Neuronal Ceroid Lipofuscinoses with CRISPR/Cas9 in Zebrafish,” appeared in the journal Human Gene Therapy. The study’s…
A comprehensive and unique collection of juvenile Batten disease induced pluripotent stem cells has become available. Juvenile Batten disease, also known as neuronal ceroid lipofuscinoses, is the result of a mutation in the CLN3 gene. The stem cell announcement was made by the Beyond Batten Disease Foundation (BBDF) and…
Two parents in Springville, Utah, lost three children in three consecutive days this summer to Batten disease, also known as neuronal ceroid lipofuscinoses. According to The Washington Post, Christopher Chappell, 20, Elizabeth, 19, and James, 15, passed away on a Friday, Saturday, and Sunday, respectively. Their joint obituary…
Yeast models of Batten disease and other lysosomal storage disorders could speed up the discovery of treatments by overcoming the restraints of animal models of the disease, a group of researchers argues in the journal Microbial Cell. Their article describes how a research approach that starts in yeast and ends…
The BATCure family survey is now live. The project aims to help develop new therapies for Batten disease by identifying target genes and small-molecule treatments for three types of Batten: juvenile CLN3 (the most common), CLN6 and CLN7. It will also study if existing drugs can be repurposed for Batten.
Early photosensitivity may be a hallmark of ceroid lipofuscinosis type 2 (CLN2) disease, according to the results of a small study. The study “Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease” was published in the journal Epilepsia. The neuronal ceroid lipofuscinoses (NCLs), or Batten disease, are a heterogeneous group of lysosomal storage disorders that…
Recent Posts
- For our rare disease family, February is about love, advocacy, and unity
- Study maps juvenile Batten disease timeline, aiding care planning
- Rare disease awareness is about a brighter future for all of us
- Advocacy and communication were key to receiving quality care in a crisis
- Miglustat may slow physical decline in juvenile Batten disease: Study
- FDA clears late infantile Batten disease gene therapy for testing
- Giving thanks for every milestone as a CLN2 Batten disease parent
- Brain abnormalities can vary by age, sex in juvenile Batten
- How Batten disease parents can drive change through advocacy
- How we celebrate Halloween with medically complex children